New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
|
|
- Marsha Pierce
- 5 years ago
- Views:
Transcription
1 New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing
2 This paper has been prepared by the International AIDS Vaccine Initiative (IAVI) as part of the background for the meeting "New Preventive Technologies - Providing new options to stop the spread of HIV/AIDS" to be held on 24 June in Dublin, Ireland. IAVI is privileged to have been asked to undertake this task and would like to acknowledge the efforts of the many other groups and individuals working towards a safe, effective, affordable, preventive HIV/AIDS for use throughout the world. For additional information, please contact: International AIDS Vaccine Initiative -European Office Postbox NG Amsterdam The Netherlands Tel Fax
3 The World Needs an AIDS Vaccine The need for a safe, effective, accessible, preventive HIV vaccine for use throughout the world is critical. More than 60 million persons have now been infected with HIV since 1983, when the virus was determined to be the cause of AIDS. More than 20 million people have already died of AIDS, and approximately 14,000 new HIV infections occur each day, with over 95% of these infections occurring in the developing world. The pandemic has dramatically decreased life expectancy in several sub- Saharan countries, created a new generation of orphans in the developing world, and threatens the very fabric of society in resource poor settings. Moreover, recent projections suggest that rapidly growing HIV epidemics in Asia, Russia and Central Europe will continue to fuel an expanding pandemic, with 70 million deaths expected by 2020 in the absence of effective worldwide AIDS prevention and control measures. Prevention programs, including education, condom and clean needle distribution and peer counselling, have had some limited success when concentrated in targeted and focused campaigns to slow the spread of HIV, but on a global scale have not been successful at blunting the epidemic. Similarly, advances in antiretroviral chemotherapy have yielded important new AIDS therapies, but the cost and complexity of their use puts them out of reach for most people in the countries and regions of the world where they are needed the most. Furthermore, even when current treatment regimens are available, in the absence of an effective vaccine, HIV infection most likely will remain an incurable, ultimately fatal disease. The best hope for preventing the spread of HIV is the development, distribution and use of safe, accessible, affordable and effective new prevention technologies such as microbicides and vaccines. A Preventive HIV/AIDS Vaccine Is Feasible A vaccine is a substance that trains the immune system to recognize and protect against a disease caused by an infectious organism or virus. In the current HIV/AIDS vaccine field, two strategies are being explored - therapeutic vaccines and preventive vaccines. This paper will focus on the status of efforts to develop a preventive vaccine for use throughout the world. A preventive vaccine is intended to prevent a disease from occurring by priming the immune system to respond to a pathogenic organism. An effective preventive HIV vaccine given before exposure will protect the vaccine recipient from HIV disease, namely by preventing the establishment of infection, with no signs of disease in the vaccine recipient and no transmission to others. Due to several observations in human natural history studies and pre-clinical vaccine studies, scientists today agree that an effective HIV vaccine capable of successfully achieving criteria for efficacy, licensure, and use in the developing world is feasible. First, a small number of individuals appear to have been repeatedly exposed to HIV, yet remain uninfected. Although the mechanisms for their resistance to infection remains undefined, they generate anti-hiv immune responses which are likely responsible for the observed resistance. Human studies have shown that anti-hiv cellular immune responses can suppress viral load to undetectable levels, slowing the progression of disease and inhibiting HIV transmission. Studies in monkeys have shown that neutralizing antibodies against HIV can completely prevent infection in monkeys challenged with simian HIV, and that monkeys immunized with live attenuated vaccines are completely protected against pathogenic simian immunodeficiency virus (SIV) challenge. More simply put, an HIV vaccine design capable of eliciting antibodies which neutralize a broad spectrum of HIV circulating strains, generating cell-mediated immune responses able to blunt viral load to undetectable levels, and capable of providing the same level of protection conferred by live attenuated vaccines, should be an achievable goal. 2
4 Current Global Efforts in AIDS Vaccine Research and Development I. Clinical Pipeline The list below summarises the different types of vaccine concepts that are currently in clinical trials. Attachment I provides an overview of the current clinical trial pipeline. Recombinant subunit vaccines. Recombinant subunits are vaccines that are produced by genetically engineering cells to produce one or more foreign genes, such as HIV genes. The gp120 developed by VaxGen was the first vaccine candidate to have undergone Phase III trial ( in 2003). More recently, Glaxo-SmithKline has evaluated a mixture of subunit proteins (Env, nef-tat) in Phase I trials, aiming to elicit cellular immune responses to multiple HIV antigens. Similarly, Chiron has recently begun Phase I trials of a V2 deleted gp140, to be used as a booster for DNA immunization, with the goal of stimulating more effective neutralizing antibodies than previously seen with gp120. Live recombinant viral vector vaccines. In this approach, HIV genetic material is placed into harmless viruses that then present pieces (e.g. proteins) of HIV to the immune system, which leads to the development of HIV-specific immune responses elicited by the vaccine. The potential advantage of the viral vector strategy is to mimic as closely as possible the efficacy of live-attenuated vaccines, while at the same time offering much greater safety. Several viral vector systems are currently being tested in clinical trials including: Alphavirus vectors (Venezuelan Equine Encephalitis replicon particles, AlphaVax, Inc); Adenovirus (Recombinant Adeno Type 5 [rad-5]; Merck) Adeno-Associated virus (AAV, Targeted Genetics-Children s Research Institute-IAVI); and Pox Viruses (e.g. Canarypox- Aventis; Fowlpox-Australian Consortium; Modified Vaccinia Ankara [MVA]- Oxford University- University Nairobi-IAVI; Vaccinia-St. Jude s Hospital; and NYVAC- EuroVac). DNA vaccines. This represents one of the newest technologies for vaccine design. Pieces of HIV DNA are incorporated into harmless plasmid DNA from bacteria and used to cause the body's cells to produce HIV proteins for the immune system that will recognize and mount responses against the virus. Preclinical studies with non-hiv vaccines have demonstrated the significant potential of this vaccine strategy as a prime for either protein or viral vector boosting. However, data thus far from clinical trials have yet to realize this potential, as DNA vaccines from Merck, Oxford University, and the NIH-Vaccine Research Centre have not reproduced the level of CD8 responses observed in small animals and non-human primates. Other groups are currently testing innovative strategies to enhance DNA immunization, including Epimmune (minigenes), Aaron Diamond-IAVI (novel promoters), Chiron (PLG microparticles), Emory-GeoVax (early and late genes), Wyeth (IL-12), NIH-VRC (IL-2), FIT Biotech (nuclear anchoring), and the University of Massachusetts-ABL (multiple clades). Data from these Phase I clinical trials will likely become available in late Synthetic peptide vaccines: Synthetic peptides are small portions of HIV proteins. Extensive basic research on potential cytotoxic T cell (CTL) and antibody epitopes of HIV have shown that the immune system will mount a response to very short peptide sections of a protein antigen when presented appropriately to the immune system. Synthetic peptides can be linked to lipid molecules (e.g. lipopeptides) to facilitate induction of cellular immune responses such as cytotoxic T cells. In addition, random libraries of peptides can be engineered to bind to antibody molecules, as a strategy to mimic (e.g. mimetope) the structure necessary to stimulate the desired antibody response. Finally, peptides can be combined as multi-peptide vaccines as a strategy for increasing the breadth of the vaccine induced response. France s ANRS is spearheading the development of lipopeptides, aimed at eliciting cell mediated immune responses against HIV. Data from Phase I trials has shown that lipopeptides can be engineered to elicit CD8 + cell mediated immune responses, and this strategy is now being explored as a booster for DNA or viral vector priming. Combination vaccines: Recognizing that protection from HIV may require a broad spectrum of immune responses including humoral (e.g. neutralizing antibodies); cellular (e.g. cytotoxic T cells, cytokines and chemokines) and mucosal immunity, scientists have designed combination regimens in attempts to elicit such broad spectrum immunity. Several combinations are now being tested in clinical trials, including among others: Canarypox + gp120 (Phase III); DNA + MVA (Phase I-II); Recombinant Adeno + Canarypox (Phase I); Canarypox + lipopeptides (Phase I); DNA + recombinant Adeno (Phase I) ; DNA + protein (Phase I) ; DNA + lipopeptides (Phase I). 3
5 Due to safety concerns, whole inactivated and live attenuated vaccine approaches are not currently being actively pursued. However, live attenuated vaccines have shown to provide complete protection in monkeys challenged with SIV and efforts to understand and identify ways of mimicking this mechanism would represent an important contribution to the field. HIV vaccines approaches recombinant protein (gp120) synthetic peptides naked DNA live-recombinant vectors (viral, bacterial) whole-inactivated virus live-attenuated virus Graph source: WHO-UNAIDS II. Efficacy Trials To date three approaches in the clinical pipeline have either completed Phase III efficacy trials, are undergoing or are being prepared to enter Phase III trials. VaxGen gp120. Recently the first two Phase III efficacy trials have been completed in North America/Europe and Thailand.The trials involved vaccines developed by VaxGen composed of recombinantly produced HIV gp120 of either clade B or clade B/E composition. Although the vaccine failed to demonstrate efficacy, the global AIDS vaccine effort gained important knowledge from the trials, including the proof that AIDS vaccine efficacy trials are indeed feasible. They also answered the important scientific question that although a monomeric gp120 vaccine induces neutralizing antibodies to T cell laboratory adapted isolates in >90% of subjects, this is not necessarily sufficient to elicit neutralizing antibodies against primary isolates of HIV, eg. those HIV isolates circulating in the population responsible for transmission. This enables the scientific community to focus future efforts on generating more effective humoral immunity and/or to stimulating cell-mediated immunity. Canarypox (Aventis) + gp120 (VaxGen). An efficacy trial is now underway in Thailand to assess the immunogenicity and protective efficacy of an avipox vectored vaccine that expresses various HIV-1 proteins as a prime, followed by the gp120 (B/E) developed by VaxGen as a boost. Data from this trial is expected to be available by Recombinant replication-defective adenovirus type 5 (Merck). An efficacy trial for the replicationdefective adenovirus type 5 vaccine vector engineered to express HIV-1 consensus clade B gag, pol and nef protein is being planned by Merck in conjunction with the HVTN, and will likely start before the end of In Phase I/II clinical trials the vaccine has elicited the most robust and durable CD8+ cellular immune response of any HIV vaccines currently in clinical trials. However data also show that prior exposure to adenovirus type 5, which occurs in approximately 40-50% of people in developed countries and over 80% in the developing world, significantly blunts the percentage of subjects who respond to the rad-5 vector. Nevertheless, this vaccine is an excellent candidate for a proof-ofconcept efficacy trial to test the hypothesis that cell medicated immune responses against HIV in the context of immunization can provide benefit upon exposure to HIV. 4
6 Major Challenges in AIDS Vaccine R&D Despite the increasing global effort and commitment to AIDS vaccine development over the past few years, to accomplish the goal of an effective, affordable and accessible preventive AIDS vaccine remains a daunting task. The following is a summary of the major challenges currently facing the field, as well as recommendations of how to address the challenges. Product development: Despite the over thirty candidates in clinical development, the global product development pipeline is narrow and duplicative and is focused primarily on testing a single scientific hypothesis (cell-mediated-immunity-based vaccines). The only CMI candidate tested for efficacy (gp120, Vaxgen), failed to prevent HIV infection, and no data from ongoing or planned efficacy trials of other candidates is expected before Therefore, the field will only learn whether vaccines aimed at eliciting cell-mediated immune responses against HIV provide any protective efficacy in Recommendation: 1) Conduct efficacy trials of the CMI-based vaccine concept; 2) Evaluate multiple immunologic parameters in these trials to gain as much information as possible on correlates of protective immunity; and 3) Develop promising candidates to address other scientific hypotheses for future efficacy testing. In this regard, greater attention should be given to developing CMI-based viral vectors not likely to face anti-vector immunity problems, strategies to elicit effective neutralizing antibodies, strategies to generate effective mucosal immunity, particularly in gut-associated lymphoid tissues where initial amplification of HIV appears to occur post-infection, and strategies utilizing novel adjuvants and vaccine delivery modalities to broaden the immune response against HIV conferred by vaccines. Scientific challenges: Limited progress has been made to date in answering certain fundamental scientific challenges such as how to elicit effective neutralizing antibodies against globally diverse and circulating strains of HIV, and how to achieve the level of protection against pathogenic SIV conferred by live attenuated vaccines. There is virtually universal agreement that neither current public sectorsupported basic research initiatives nor current private sector funded product development programs will adequately address these scientific challenges. Recommendation: The creation of adequately resourced scientific consortia, involving the collaboration of leading laboratories and scientists, represents an effective mechanism to bridge the gap between basic research and product development and has the potential for success to tackle these challenges. Process development and manufacturing: Many candidates in the current pipeline are not developable due to limited attention to process development and manufacturing issues. Recommendation: Process development resources need to be provided for the most promising candidates, with key milestones clearly delineated that are similar to those used to advance candidates through clinical development. In addition, close linkages need to be established between the applied research/translational studies aimed at optimising, combining and comparing candidate vaccines with those process development studies aimed at ensuring that the leading candidates can in fact be developed. Clinical trials infrastructure: Clinical trials capacity in preparation for efficacy trials is limited, particularly in regions of the world where HIV incidence is greatest. Several stakeholders have carried out important epidemiology, HIV prevention and Phase I vaccine trials. However, they have not focused investment comprehensively on preparation for efficacy trials. Furthermore regulatory capacity in the developing world needs to be significantly strengthened. Recommendation: Establish HIV vaccine trials regional centres in the developing world, which contain the core clinical, laboratory, cohort, logistics, public health and political elements required for successful conduct of efficacy trials. A long-term commitment to these sites, including the provision of significant resources for training and infrastructure, are essential for the creation and maintenance of such centres. 5
7 The Way Forward It is estimated that approximately US$ 600 million is currently spent annually on global AIDS vaccine R&D. This is clearly inadequate given the urgency of the pandemic. A significant increase in current resources dedicated to this effort is required to ensure real progress in the next decade, and that these resources should be focused on addressing the scientific challenges, prioritising the most promising candidates, establishing facilities to produce clinical-grade materials and preparing for large-scale manufacturing, ensuring that effective regulatory processes are established, and ensuring that access to successfully licensed AIDS vaccines will be accelerated for those that need them most in the developing world. 6
8 Attachment I: Global Clinical Trial Pipeline (updated May 2004) Candidates Principal Developer Subtype Phase Subunits gp120 VaxGen B No significant efficacy gp120 VaxGen B/E No significant efficacy gp120+nef-tat GSK B Phase I gp140 V2 deleted Chiron B Phase I gp160 MN/LAI-2 Aventis B Phase I EnvPro St Jude's Hospital D Phase I tat ISS B Phase I Viral Vectors radeno 5 - gag, pol, nef Merck B Phase III initiates Q4 04, data 2008 radeno 5 - gag Merck B Phase I/II ALVAC vcp env (E), Aventis B/E Phase III gag/pol (B) ALVAC vcp205 - env, gag, Aventis B Phase II pol MVA - gag + CTL epitopes IAVI-Oxford-Kenya A Phase I/II FPV - gag, RT, rev, tat, vpu, Australian Thai Consortium B Phase I/II env NYVAC - gag, pol, nef, env EuroVac C Phase I VEE - gag AlphaVax C Phase I AAV - gag, pro, rt IAVI-CRI-TGC C Phase I Vaccinia - multi, env St. Jude's Hospital B, D Phase I DNA gag+ CTL epitopes IAVI - Oxford - Kenya A Phase I/II env-gag, pol, nef-tat IAVI - ADARC C Phase I gag Merck B Phase I/II 21 CTL epitopes fm gag, pol, Epimmune B Phase I env, nef, rev, vpr nef (nuclear anchoring) FIT Biotech B Phase I env, gag, pro, RT, tat, vpu, rev Emory B Phase I gag, env gp140 + Chiron B Phase I/II microparticles gag, pol, nef, env + IL-2 NIH-VRC A, B, C Phase I gag, rt, env, tat, rev, vpu Vical B Phase I gag + IL-12 Wyeth B Phase I gag, RT, rev, tat, vpu, env Australian Thai Consortium B Phase I/II gag + 5 env U. Mass - ABL A, B, C, E Phase I Peptides Lipopeptides 5, CTL epitopes ANRS - Aventis B Phase I fm gag, nef, pol Lipopeptides 6T, CTL epitopes ANRS - Aventis B Phase I fm gag, nef and env Lipopeptides 4T, CTL epitopes ANRS - Aventis B Phase I fm gag, pol, RT, nef poly-epitopic - env, gag, nef Wyeth B Phase I Prime-Boost Combination ALVAC vcp gp120 Aventis-VaxGen B, E Phase III, data 2008 DNA + MVA IAIV-Oxford-Kenya A Phase I/II DNA + Fowlpox Australian Thai Consortium B Phase I/II DNA + Adeno VRC B Phase I/II Adeno + ALVAC vcp205 Merck-Aventis B Phase I ALVAC + Lipo-peptides Aventis + ANRS B Phase I DNA + Lipo-peptides ANRS B Phase I DNA+V2 deleted gp140 Chiron B Phase I DNA + gp120 U. Mass - ABL A, B, C, E Phase I 7
9 8
SCIENTIFIC BLUEPRINT 2000: ACCELERATING GLOBAL EFFORTS AIDS VACCINE DEVELOPMENT JULY
S C I E N T I F I C B L U E P R I N T 2 0 0 0 SCIENTIFIC BLUEPRINT 2000: ACCELERATING GLOBAL EFFORTS IN AIDS VACCINE DEVELOPMENT JULY 2000 S C I E N T I F I C B L U E P R I N T 2 0 0 0 SCIENTIFIC BLUEPRINT
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationEDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationHIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง
HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally
More informationMay HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationBiomedical Engineering for Global Health. Lecture 10 HIV/AIDS vaccine development
Biomedical Engineering for Global Health Lecture 10 HIV/AIDS vaccine development Review of lecture 9 How do vaccines work? Types ofvaccines: Review of lecture 9 Are vaccines effective? -Edward Jenner s
More informationThe Potential For Harnessing the Immune System to Control HIV
The Potential For Harnessing the Immune System to Control HIV Gordon Dickinson, MD Chief, Infectious Diseases, U Miami School of Medicine, and Co-Director, Special Immunology, Miami VA Medical Center The
More informationPRACTICE POINTS AIDS Vaccine 2001: Looking to the Future
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future 1 Ronald T. Mitsuyasu 1 Associate Professor of Medicine, University of California Los Angeles, and Director of the UCLA CARE Center, UCLA Medical
More informationProgress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationThe History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationExpansion of Kangemi Clinic Project Budget & IAVI s Mission and Activities
Let us not underestimate the resources required to conduct this battle. In this inter-dependent and globalised world, we have indeed again become the keepers of our brother and sister. That cannot be more
More informationStrategies for an HIV vaccine
Strategies for an HIV vaccine Norman L. Letvin J Clin Invest. 2002;110(1):15-27. https://doi.org/10.1172/jci15985. Perspective The development of an HIV vaccine poses an unprecedented challenge to the
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationThe Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
More informationHIV vaccine research and development
HIV vaccine research and development What is an HIV vaccine and how does it work? An HIV vaccine is a substance given to the body to teach it to defend itself against HIV. A successful preventative HIV
More informationBiotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationKEY ELEMENTS FOR SUCCESSFUL INTERVENTION (1)
KEY ELEMENTS FOR SUCCESSFUL INTERVENTION (1) Mobilization of political will and commitment Good surveillance Learn and adapt from past experiences Unified national planning Rapid implementation KEY ELEMENTS
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationFoot and Mouth Disease Vaccine Research and Development in India
Foot and Mouth Disease Vaccine Research and Development in India R.Venkataramanan Indian Veterinary Research Institute, Hebbal, Bangalore 560 024 Foot and Mouth Disease in India Present Status Large Susceptible
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationPart One Immunology and Vaccination Strategies for AIDS and TB
Part One Immunology and Vaccination Strategies for AIDS and TB AIDS and Tuberculosis: A Deadly Liaison. Edited by Stefan H.E. Kaufmann and Bruce D. Walker Copyright Ó 2009 WILEY-VCH Verlag GmbH & Co. KGaA,
More informationBBS 2711 Virology. Virus Vaccines
BBS 2711 Virology Virus Vaccines Dr Paul Young, Department of Microbiology & Parasitology. p.young@mailbox.uq.edu.au Virus Vaccines First vaccine developed by Jenner in late 1700's against smallpox virus
More informationMicro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people
Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationMid-term Review of the UNGASS Declaration of. Commitment on HIV/AIDS. Ireland 2006
Mid-term Review of the UNGASS Declaration of Commitment on HIV/AIDS Ireland 2006 Irish Role in Global Response Just as the HIV/AIDS epidemic is a global threat, addressing the challenge of the epidemic
More informationViral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP
Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal
More informationGroup 4: Science and Vaccine Development Recommendations to the MOPH on the RV 144 HIV Phase III Vaccine Trial
rprise HO-Enter WH Group 4: Science and Vaccine Development Recommendations to the MOPH on the RV 144 HIV Phase III Vaccine Trial Dr. Wai Lin Htun Mahidol University 0 Recommendation 1: Durability of Vaccine
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationAIDS killed 2.5 million people in 2007.
HIV Vaccines: Time for a New Vision Annie De Groot MD EpiVax GAIA Vaccine Foundation Brown University and now... Institute for Immunology and Informatics, University of Rhode Island University i of Georgia
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationAIDS VACCINE BLUEPRINT 2006
AIDS VACCINE BLUEPRINT 2006 Actions to Strengthen Global Research and Development A partner of the Global HIV Vaccine Enterprise AIDS VACCINE BLUEPRINT 2006 Actions to Strengthen Global Research and Development
More informationHIV-1 Vaccine Trials: Evolving Concepts and Designs
Send Orders of Reprints at bspsaif@emirates.net.ae 274 The Open AIDS Journal, 2012, 6, 274-288 HIV-1 Vaccine Trials: Evolving Concepts and Designs Open Access Missa P. Sanou 1, Anne S. De Groot 2, Michael
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationAn AIDS vaccine: Why is it so difficult?
An AIDS vaccine: Why is it so difficult? Jaap Goudsmit, MD, PhD Professor of Poverty-related Communicable Diseases, AMC Chairman of the Board CPCD CSO, Crucell Holland BV An AIDS vaccine: Why is it so
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationUnited Nations General Assembly June 8, 2011
Remarks by Dr. Mathilde Krim United Nations General Assembly June 8, 2011 I am Mathilde Krim, the Founding Chairman of amfar, The Foundation for AIDS Research. This is a not-for-profit foundation based
More informationthe Office of Research Application Portal: Materials to submit:
Title: PAR 17 237: Centers for AIDS Research (P30) Slots: 1 Internal Deadline: LOI: External Deadline: Award Information: Submission Process: May 26, 2018, 5pm PDT 30 days prior to the application due
More informationFUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
More informationThe Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014
The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase
More informationQuestions and answers: HVTN 084 vaccine trial
1. What is the HVTN 084 trial? Questions and answers: HVTN 084 vaccine trial Version 2 Last updated December 2, 2010 HVTN 084 is the name of a clinical trial to test the safety of 2 experimental HIV vaccines.
More informationHIV-1 Vaccine Development: Recent Advances in the CTL Platform Spotty Business ACCEPTED
JVI Accepts, published online ahead of print on 7 November 2007 J. Virol. doi:10.1128/jvi.01634-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationHealth Task Force Workplan
2006/SOM 3/HTF/021 Agenda Item: VI Health Task Force Workplan 2006-2007 Purpose: Information Submitted by: Chair Health Task Force Meeting Da Nang, Viet Nam 14 15 September 2006 APEC HEALTH TASK FORCE
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationThe Struggle with Infectious Disease. Lecture 6
The Struggle with Infectious Disease Lecture 6 HIV/AIDS It is generally believed that: Human Immunodeficiency Virus --------- causes ------------- Acquired Immunodeficiency Syndrome History of HIV HIV
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationSAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
More informationEconomics of Vaccine Development A Vaccine Manufacturer s Perspective
Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria
More informationImproving Influenza vaccines: Looking ahead
Improving Influenza vaccines: Looking ahead Gerd Sutter gerd.sutter@lmu.de ESWI Flu Summit - Brussels 30.09.2015 First 20th century pandemic - The Spanish Flu Courtesy: A. Garcia-Sastre Influenza A/CDC/1918
More informationChikungunya Vaccines in the Pipeline
Chikungunya Vaccines in the Pipeline Health impact Public health burden : 1.3 billion people live in areas endemic for Chikungunya. Prevalent in ~60 countries over the world Has high attack rates and the
More informationDEVELOPMENT. The European Union confronts HIV/AIDS, malaria and tuberculosis. A comprehensive strategy for the new millennium EUROPEAN COMMISSION
DEVELOPMENT The European Union confronts HIV/AIDS, malaria and tuberculosis A comprehensive strategy for the new millennium EUROPEAN COMMISSION DE 121 FEB 2004 A global challenge Every minute, 11 people
More informationIntroduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.
Introduction In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology. - Genomics: fasten antigen discovery for complex pathogens
More informationFostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
More informationAcute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).
Influenza glossary Adapted from the Centers for Disease Control and Prevention, US https://www.cdc.gov/flu/glossary/index.htm and the World Health Organization http://www.wpro.who.int/emerging_diseases/glossary_rev_sept28.pdf?ua=1
More informationViiV Healthcare s Position on Prevention in HIV
ViiV Healthcare s Position on Prevention in HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status quo and find new ways of navigating the challenges
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationMID-TERM EXAMINATION
Epidemiology 227 May 2, 2007 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 75 questions and 11 pages on the examination. Each question will count one point. Notify
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationFMD VACCINE AND VACCINATION. Ahmad Al-Majali Dean, Faculty of Vet Medicine JUST Jordan
FMD VACCINE AND VACCINATION Ahmad Al-Majali Dean, Faculty of Vet Medicine JUST Jordan General Considerations on FMD vaccination The currently used FMD vaccines are killed virus preparations that are pure,
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationOngoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)
HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype
More informationWITH AN ESTIMATED7500 INcident
ORIGINAL CONTRIBUTION Vaccine-Induced HIV Seropositivity/Reactivity in ninfected HIV Vaccine Recipients Cristine J. Cooper, PhD Barbara Metch, MS Joan Dragavon, MLM Robert W. Coombs, MD, PhD Lindsey R.
More informationDevelopment of Broadly Reactive HIV-1/AIDS Virus-like Particle Vaccines. Sean Patrick McBurney. B.S. Microbiology, University of Pittsburgh, 2004
Development of Broadly Reactive HIV-1/AIDS Virus-like Particle Vaccines by Sean Patrick McBurney B.S. Microbiology, University of Pittsburgh, 2004 Submitted to the Graduate Faculty of School of Medicine
More informationLetter from the CEO. Dear Friends of IAVI,
IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationDiversifying the Pipeline of Product Concepts for an HIV Vaccine. RFP Overview and Guidelines
Diversifying the Pipeline of Product Concepts for an HIV Vaccine RFP Overview and Guidelines 1 Table of Contents 1. Introduction. 3 2. Background a. Foundation s HIV Vaccine Strategy 3 b. CAVD Framework..
More informationThe challenge of an HIV vaccine from the antibody perspective. Dennis Burton The Scripps Research Institute
The challenge of an HIV vaccine from the antibody perspective Dennis Burton The Scripps Research Institute AIDS Pandemic Nov 2005 North America 1.2 million [650 000 1.8 million] Caribbean 300 000 [200
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationSPECIFIC ANTIINFECTIOUS IMMUNITY. colostral immunity. administration of antibodies VIRULENT VACCINE INACTIVATED VACCINE
INDUCTION OF IMMUNITY AGAINST INFECTION SPECIFIC ANTIINFECTIOUS IMMUNITY active passive S AND VACCINATION infection vaccination colostral immunity administration of antibodies VIRULENT MODIFIED LIVE INACTIVATED
More informationCOSTA RICA KEY. Public health is the study of how diseases spread in a population and the measures used to control them.
COSTA RICA KEY Controlling the Pandemic: Public Health Focus Just 25 years since it was first reported, HIV/AIDS has become one of the world s greatest public health crises. More than 39 million people
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationEC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
More informationD-LAB HEALTH SP 725. Jose Gomez-Marquez
SP 725 Jose Gomez-Marquez 1 Vaccine Preventable Diseases Causes of 2.5 million child deaths out of 10.5 million child deaths globally, 2002 Source: WHO Wkly Epidemiol Rec. (2006) 81:189-196. 2 Rationale
More informationUpdate on Tuberculosis Vaccines
March 27, 2014 Update on Tuberculosis Vaccines - 2014 Tom Evans MD CEO, Aeras TB is Mother Nature s AERAS GLOBAL number TB VACCINE one FOUNDATION killer over the past centuries TB is spread through the
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationVACCINE ENGINEERING Dr.T.V.Rao MD
VACCINE ENGINEERING Dr.T.V.Rao MD DR.T.V.RAO MD 1 HISTORICAL PICTURE OF VACCINATION DR.T.V.RAO MD 2 WHAT IS A VACCINE A vaccine is any preparation intended to produce immunity to a disease by stimulating
More informationStructure of HIV. Virion contains a membrane envelope with a single viral protein= Env protein. Capsid made up of Gag protein
Structure of HIV Virion contains a membrane envelope with a single viral protein= Env protein Important in receptor recognition Capsid made up of Gag protein (group-specific antigen) Icosahedral Interior
More informationBOSTWANA KEY. Controlling the Pandemic: Public Health Focus
BOSTWANA KEY Controlling the Pandemic: Public Health Focus Just 25 years since it was first reported, HIV/AIDS has become one of the world s greatest public health crises. More than 39 million people worldwide
More informationUNRAVELING THE MYSTERY BEHIND HIV/AIDS
PRESS RELEASE 3 MAR 2010 UNRAVELING THE MYSTERY BEHIND HIV/AIDS New findings by Nobel Laureate shed light on the elusive AIDS virus and may lead to effective HIV vaccine development 1. Professor Francoise
More informationLearning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda
Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda Pontiano Kaleebu MRC-UVRI Uganda Research Unit on AIDS & UVRI-IAVI HIV Vaccine Programme Past 1987 Cohort studies
More information